» Articles » PMID: 2504717

Pseudomonas Exotoxin: Chimeric Toxins

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 1989 Sep 15
PMID 2504717
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Pseudomonas exotoxin binds to and enters cells by receptor-mediated endocytosis. Within the cell it requires exposure to low pH to enable it to translocate to the cell cytoplasm where it inhibits protein synthesis by ADP-ribosylating elongation factor 2. The toxin has three main structural domains whose functions are: Ia, cell binding; II, translocation; and III, ADP-ribosylation. Key amino acids have been identified within each domain that are required for the function of the toxin. Chimeric toxins were made originally by using chemical cross-linking reagents to couple Pseudomonas exotoxin (or other toxins) to cell-binding proteins. More recently, a variety of Pseudomonas exotoxin-related chimeric toxins have been made by gene fusion technology. These chimeric toxins may be useful clinically for treating various diseases and experimentally for understanding receptor function.

Citing Articles

Discovery of mono-ADP ribosylating toxins with high structural homology to Pseudomonas exotoxin A.

Masuyer G, Taverner A, MacKay J, Lima Marques A, Wang Y, Hunter T Commun Biol. 2025; 8(1):413.

PMID: 40069285 PMC: 11897225. DOI: 10.1038/s42003-025-07845-y.


Crystal Structure of Exotoxin A from Pathogenic Species.

Masuyer G Toxins (Basel). 2020; 12(6).

PMID: 32549399 PMC: 7354439. DOI: 10.3390/toxins12060397.


HER2 monoclonal antibodies that do not interfere with receptor heterodimerization-mediated signaling induce effective internalization and represent valuable components for rational antibody-drug conjugate design.

De Goeij B, Peipp M, de Haij S, van den Brink E, Kellner C, Riedl T MAbs. 2014; 6(2):392-402.

PMID: 24492309 PMC: 3984328. DOI: 10.4161/mabs.27705.


Structural complementation of the catalytic domain of pseudomonas exotoxin A.

Boland E, Van Dyken C, Duckett R, McCluskey A, Poon G J Mol Biol. 2013; 426(3):645-55.

PMID: 24211469 PMC: 3997303. DOI: 10.1016/j.jmb.2013.11.002.


Novel Therapy for Atherosclerosis Using Recombinant Immunotoxin Against Folate Receptor β-Expressing Macrophages.

Furusho Y, Miyata M, Matsuyama T, Nagai T, Li H, Akasaki Y J Am Heart Assoc. 2012; 1(4):e003079.

PMID: 23130174 PMC: 3487340. DOI: 10.1161/JAHA.112.003079.